Trial · NCT04546724
Outcomes15
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With a Seroprotective CHIKV Antibody Level for Baseline Negative Subjects 28 Days Post-vaccination | on Day 29 after single vaccination | The Per-Protocol population used for immunogenicity analyses, is based on participants without major protocol deviations that could impact the immune response. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | CHIKV-specific Neutralizing Antibody Titers | Until Day 180 | The Per-Protocol population used for immunogenicity analyses, is based on participants without major protocol deviations that could impact the immune response. | Antibody Titers | GEOMETRIC_MEAN |
| SECONDARY | Number of Participants With Seroprotective CHIKV Antibody Level | Until Day 180 | The Per-Protocol population used for immunogenicity analyses, is based on participants without major protocol deviations (PDs) that could impact the immune response.~Counts of participants per time point vary: baseline AND post-line µPRNT result are needed at a given timepoint; results for a specific timepoint were excluded in case of major PD (e.g., major time window deviation resulted in exclusion of a result for a given visit/ time point, results from earlier/ later visits were included) | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Seroconversion | Until Day 180 | The Per-Protocol population used for immunogenicity analyses, is based on participants without major protocol deviations that could impact the immune response. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Fold Change of CHIKV-specific Neutralizing Antibody Titers Compared to Baseline | until Day 180 | The Per-Protocol population used for immunogenicity analyses, is based on participants without major protocol deviations that could impact the immune response. | fold increase | MEAN |
| SECONDARY | Number of Participants Reaching an X-fold Change in CHICKV-specific Neutralizing Antibody Titer Compared to Baseline | until Day 180 | The Per-Protocol population used for immunogenicity analyses, is based on participants without major protocol deviations that could impact the immune response. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Unsolicited AEs | Until Day 29 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Solicited Injection Site AEs | within 10 days post-vaccination | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Solicited Systemic AEs | within 10 days post-vaccination | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Adverse Events | until Day 180 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Related Adverse Events | until Day 180 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Serious Adverse Event | until Day 180 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Related Serious Adverse Event | until Day 180 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Adverse Event of Special Interest | within 21 days post-vaccination | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Related Adverse Event of Special Interest | within 21 days post-vaccination | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04546724/outcomes